Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Invesco Preferred ETF (PGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Invesco Preferred ETF — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.89 (market cap $977.37M), while Invesco Preferred ETF trades at $10.08 (market cap $3.61B). The key difference: Invesco Preferred ETF is far larger — about 3.7× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Invesco Preferred ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Invesco Preferred ETF for 96 Days on average.
| MRVI | PGX | |
|---|---|---|
Market Cap | $977.37M | $3.61B |
Volume | 2,742,564 | 11,813,431 |
Sector | Health | — |
52-Week High | $9.00 | $11.61 |
52-Week Low | $2.83 | $9.95 |
Typical Hold Time | 0 Days | 96 Days |
Enterprise Value | $1.08B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
PGX trades at $10.065, up 0.25% on the day, with a bearish technical signal from moving averages and oscillators. Key financial ratios such as P/E, P/S, and ROE are unavailable in the provided data. The company has scheduled dividends for July and September 2026, each at $0.06 per share, indicating a commitment to shareholder returns despite the lack of recent financial disclosures.
The outlook for PGX is cautious due to bearish technical indicators and missing fundamental data, which limits visibility into its financial health. Investment opportunities hinge on future earnings reports clarifying profitability and growth. Risks include potential volatility from incomplete financial transparency and market sentiment shifts. Investors should await updated SEC filings for a clearer assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Invesco Preferred ETF
The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Read more on PGX →
